CLLS
Price:
$3.09
Market Cap:
$231.33M
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma ...[Read more]
Industry
Biotechnology
IPO Date
2015-03-24
Stock Exchange
NASDAQ
Ticker
CLLS
According to Cellectis S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -4.61. This represents a change of -117.24% compared to the average of 26.74 of the last 4 quarters.
The mean historical PE Ratio of Cellectis S.A. over the last ten years is -7.27. The current -4.61 PE Ratio has changed 6.24% with respect to the historical average. Over the past ten years (40 quarters), CLLS's PE Ratio was at its highest in in the September 2025 quarter at 117.92. The PE Ratio was at its lowest in in the June 2018 quarter at -41.80.
Average
-7.27
Median
-7.63
Minimum
-17.41
Maximum
-0.98
Discovering the peaks and valleys of Cellectis S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.00%
Maximum Annual PE Ratio = -0.98
Minimum Annual Increase = -79.68%
Minimum Annual PE Ratio = -17.41
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -7.03 | 70.46% |
| 2024 | -4.13 | 160.00% |
| 2023 | -1.59 | 61.71% |
| 2022 | -0.98 | -77.67% |
| 2021 | -4.39 | -74.75% |
| 2020 | -17.41 | 111.77% |
| 2019 | -8.22 | -8.08% |
| 2018 | -8.94 | -15.39% |
| 2017 | -10.57 | 12.28% |
| 2016 | -9.41 | -79.68% |
The current PE Ratio of Cellectis S.A. (CLLS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.25
5-year avg
-3.62
10-year avg
-7.27
Cellectis S.A.’s PE Ratio is greater than Alto Neuroscience, Inc. (-9.50), less than AC Immune S.A. (-2.74), less than Aldeyra Therapeutics, Inc. (-3.88), greater than Amarin Corporation plc (-9.43), greater than Alpha Tau Medical Ltd. (-15.54), less than Larimar Therapeutics, Inc. (-1.78), less than Silence Therapeutics plc (-3.71), greater than DBV Technologies S.A. (-8.91), less than Mereo BioPharma Group plc (-1.37), less than Korro Bio, Inc. (-1.19),
| Company | PE Ratio | Market cap |
|---|---|---|
| -9.50 | $753.47M | |
| -2.74 | $235.10M | |
| -3.88 | $106.17M | |
| -9.43 | $315.21M | |
| -15.54 | $889.71M | |
| -1.78 | $296.96M | |
| -3.71 | $316.00M | |
| -8.91 | $416.60M | |
| -1.37 | $48.68M | |
| -1.19 | $115.56M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cellectis S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cellectis S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cellectis S.A.'s PE Ratio?
How is the PE Ratio calculated for Cellectis S.A. (CLLS)?
What is the highest PE Ratio for Cellectis S.A. (CLLS)?
What is the 3-year average PE Ratio for Cellectis S.A. (CLLS)?
What is the 5-year average PE Ratio for Cellectis S.A. (CLLS)?
How does the current PE Ratio for Cellectis S.A. (CLLS) compare to its historical average?